Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can an AI chatbot coach people away from type 2 diabetes?

NCT ID NCT07824154

Prevention Sponsor: Emory University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 17, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

Researchers are testing an AI chatbot that gives personalized, culturally tailored advice on nutrition, physical activity, and goal setting to adults at risk for type 2 diabetes. About 30 adults aged 18 to 55 will use the chatbot for 6 weeks. The study will check whether the chatbot is easy to use, helpful, and trustworthy, and whether health behavior data can be collected for larger future studies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an AI-powered diabetes prevention chatbot that gives personalized nutrition and fitness coaching
What this could lead to
If the chatbot proves easy to use and helpful, it could offer a low-cost way to deliver personalized diabetes prevention coaching to people at risk. It could also inform larger studies testing whether such tools change health behaviors.
What could go wrong
This is a small, short feasibility study with about 30 participants over 6 weeks. It measures engagement and data collection, not whether the chatbot prevents diabetes. The approach may not work for everyone or translate into lasting behavior change.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have at least one of the following diabetes risk factors: * HbA1C of 5.7-6.4% * BMI of 18.5 - 24.9 kg/m\^2 * Fasting plasma glucose 100 - 125 mg/dL * Family history of type 2 diabetes in first-degree relatives (parents, siblings, or children) * History of gestational diabetes * Membership in a high-risk ethnic group (African American, Hispanic, Native American, Asian American, Pacific Islander) * Access to a smartphone or computer with internet * English reading and writing proficiency * Be willing to use the chatbot at least 3 times per week * Be able to provide informed consent * Availability for the 6-week study duration * Able to perform resistance training exercises Exclusion Criteria: * Are diagnosed with type 1 or type 2 diabetics * Have uncontrolled hypertension (higher than 160/100 mmHg) * Have cardiovascular disease * Are pregnant or planning to be pregnant * Are actively undergoing treatment for cancer * Have an eating disorder * Have chronic kidney disease * Are enrolled in another research study or participating in a structured lifestyle program

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pre diabetes are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glucose intolerance prediabetes syndrome type 2 diabetes mellitus prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pre diabetes TYPE2 diabetes

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Emory University

    Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.